ETILX
Unless otherwise noted, all data is as of 12/31/2024. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Morningstar ratings are based on risk-adjusted returns.
Seeks to provide long-term capital appreciation.
A diversified mutual fund representing our "best ideas" for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.
Seeking to invest in companies best positioned to participate in long-term secular investment themes.
Focused on identifying and investing in companies capable of increasing profitability and growth by serving well the needs of customers, employees, suppliers, communities, the environment, and society broadly.
Portfolio is constructed with goals of high internal diversification and low market correlation.
Eventide Gilead Fund | As of 04/01/2025 YTD | |||||||
---|---|---|---|---|---|---|---|---|
Class I | -8.18% | 0.25 | -0.02 | -6.74 | 7.07 | 9.30 | 12.90 | 02/02/2010 |
Class A without load | -8.25% | 0.20 | -0.26 | -6.97 | 6.82 | 9.03 | 13.71 | 10/28/2009 |
Class A with 5.75% load | -13.54% | -5.57 | -5.99 | -8.79 | 5.56 | 8.38 | 13.27 | 10/28/2009 |
Class C | -8.42% | 0.00 | -1.03 | -7.67 | 6.00 | 8.20 | 12.84 | 10/28/2009 |
Class N | -8.23% | 0.22 | -0.22 | -6.93 | 6.86 | 9.08 | 12.42 | 07/08/2008 |
Benchmarks | ||||||||
Bloomberg US Mid Cap Growth Index3 | -5.80% | 2.76 | 15.76 | 2.15 | 10.82 | 10.74 | 10.63 | 07/08/2008 |
Russell Midcap Growth Index4 | -6.25% | 8.14 | 22.10 | 4.04 | 11.47 | 11.54 | 11.35 | 07/08/2008 |
Eventide Gilead Fund, Class I | -1.94 | 1.12 | 33.09 | -2.33 | 34.10 | 55.42 | 11.64 | -33.92 | 22.76 | -0.02 | |
Bloomberg US Mid Cap Growth Index3 | -0.01 | 7.27 | 22.55 | -6.00 | 34.34 | 32.06 | 18.73 | -24.01 | 21.18 | 15.76 | |
Russell Midcap Growth Index4 | -0.20 | 7.33 | 25.27 | -4.75 | 35.47 | 35.59 | 12.73 | -26.72 | 25.87 | 22.10 | |
Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at eventidefunds.com/prospectus. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836). The returns shown do not reflect the deduction in taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. Performance figures greater than 1 year are annualized. |
Morningstar ratings are based on risk-adjusted returns. Morningstar rankings are based on total returns.
| Standard Deviation12 | Beta13 | Alpha(%)14 | R-Squared(%)15 | ||||
---|---|---|---|---|---|---|---|---|
| 3-yr | Inception16 | 3-yr | Inception16 | 3-yr | Inception16 | 3-yr | Inception16 |
Eventide Gilead Fund, Class I | 22.16 | 19.90 | 0.99 | 1.08 | -8.86 | -0.30 | 90.11 | 86.51 |
Bloomberg US Mid Cap Growth Index3 | 21.23 | 17.12 | 1.00 | 1.00 | - | - | 100 | 100 |
Russell Midcap Growth Index4 | 22.47 | 17.57 | 1.04 | 1.01 | 2.09 | 0.34 | 97.19 | 97.89 |
Holding | Weight (28.08%) |
---|---|
Xometry Inc AI-enabled marketplace for on-demand manufacturing | 4.39% |
The Trade Desk Inc Digital advertising platform for display, social, and video campaigns | 3.37% |
Verona Pharma PLC Develops new therapies for severe respiratory diseases, including COPD, asthma, and cystic fibrosis | 3.00% |
Toast Inc Develops cloud software to equip restaurants to thrive | 2.93% |
Global-e Online Ltd Develops end-to-end cross-border platforms for eBusiness | 2.74% |
Guardant Health Inc Cell diagnostics for cancer patients | 2.40% |
Trane Technologies PLC HVAC systems for energy efficiency and reduced carbon emissions | 2.39% |
Old Dominion Freight Line Inc Inter-regional and multi-regional motor carrier | 2.36% |
Monday.com Ltd Platform for streamlining team collaboration, project management, and productivity | 2.34% |
Scholar Rock Novel therapeutics for neuromuscular disorders and obesity | 2.16% |
Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member
Finny Kuruvilla, MD, PhD, serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for Eventide’s Strategic Growth, Healthcare & Life Sciences, and Technology Strategies. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide.
Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.
This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.
The Morningstar Rating™ for funds, or ‘star rating’, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10- year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Ratings are determined monthly and subject to change.
% Rank in Category is the fund’s percentile rank for the specified time period relative to all funds that have the same Morningstar category. The highest (or most favorable) percentile rank is 1 and the lowest (or least favorable) percentile rank is 100. The top-performing fund in a category will always receive a rank of 1. Percentile ranks within categories are most useful in those categories that have a large number of funds.© 2025 Morningstar. All Rights Reserved. Morningstar is an independent provider of financial information. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.
Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.
Eventide 1561-2179 - 04/02/2025 09:10am